Diagnosis and Treatment of Cholangiocarcinoma in Era of Precision Medicine

Yan Sun,Bao-Rong Chi
DOI: https://doi.org/10.11569/wcjd.v25.i24.2167
2017-01-01
Abstract:Cholangiocarcinoma (CCA) is a kind of relatively rare biliary system malignant tumor that has an extremely poor prognosis due to the lack of understanding of the molecular pathogenesis and the shortage of effective therapeutic methods.The adoption of precision medicine and cancer genomic profiling enhance our understanding of tumor molecular pathogenesis and can help identify potential therapeutic targets.Research has identified significant differences between intrahepatic and extrahepatic CCA,including epidemiology,etiology,molecular mechanisms,therapeutic methods and prognosis.The first important step towards personalized precise medicine strategy is classification of CCA and identification of the unique characteristics of each subtype.Hopefully,the acquisition and integration of omics information of CCA subtypes,and based on this,the development of effective targeted therapy will improve the prognosis and overall survival of patients.
What problem does this paper attempt to address?